Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

LGD-4033 and Ondansetron Interaction: Avoid | Peptide Database

Compound Profiles LGD-4033 Selective Androgen Receptor Modulator | Lean Mass LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its t

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

LGD-4033

Selective Androgen Receptor Modulator | Lean Mass

LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.

Ondansetron

5-HT3 Antagonist | Anti-Nausea On Cycle

Ondansetron exerts its anti-emetic effects through selective antagonism of serotonin 5-HT3 receptors. These receptors are concentrated in two key areas relevant to nausea: the vagal afferent nerve terminals in the gastrointestinal tract and the chemoreceptor trigger zone (CTZ) in the area postrema of the brainstem.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take LGD-4033 with Ondansetron?

Combining LGD-4033 with Ondansetron is not recommended. Both LGD-4033 and Ondansetron carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is LGD-4033 and Ondansetron safe together?

This combination carries significant risk. Both LGD-4033 and Ondansetron carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between LGD-4033 and Ondansetron?

Both LGD-4033 and Ondansetron carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time LGD-4033 and Ondansetron?

LGD-4033 has a half-life of ~24-36 hours and Ondansetron has a half-life of ~4 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
comparison

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for at…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Community Research

Join others researching GHRP-2 — share findings, ask questions, and learn from real experiences GHRP-2 is a synthetic growth hormone secretagogue that stimulates the pituitary gland to release growth hormone. It is one of the most potent members of the GHRP family, being 2-3 times more effective than GHRP-6 in stimulating GH release. Originally developed as a diagnostic agent for growth hormone deficiency, it works by mimicking ghrelin and binding to the GHS-R1a receptor. GHRP-2 acts as a synthetic agonist of ghrelin, binding to the growth hormone secretagogue receptor (GHS-R1a) in the hypothalamus and pituitary. This stimulates cAMP production and promotes pulsatile release of endogenous growth hormone without suppressing natural feedback loops. It works synergistically with GHRH to amplify GH secretion beyond what either peptide achieves alone.

Source: peptide-db.com ↗

Does Cerebrolysin actually work for stroke recovery or is the evidence mixed?

Evidence is mixed. Large meta-analysis of 1,879 stroke patients showed NIHSS (neurological function) superiority, but an independent analysis found no significant improvement in modified Rankin Scale (functional outcomes). Cerebrolysin appears to have early neurological benefits without clear long-term functional recovery advantage.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Tamoxifen is administered orally as a tablet, typically tamoxifen citrate. It is well absorbed from the gastrointestinal tract with peak plasma levels reached within 4-7 hours. The extremely long half-life of 5-7 days means steady-state concentrations are achieved after approximately 4 weeks of daily dosing. Can be taken with or without food. Due to the long half-life, missed doses have minimal impact on therapeutic levels. Post-cycle therapy (standard tapered protocol) 40mg daily for 2 weeks, then 20mg daily for 2 weeks Once daily for 4 weeks total Oral Post-cycle therapy (moderate) 20mg Once daily for 4-6 weeks Post-cycle therapy (extended, heavy suppression) 40mg daily for 2 weeks, then 20mg daily for 4 weeks Once daily for 6 weeks total On-cycle gynecomastia prevention 10-20mg Once daily throughout cycle Breast cancer treatment (medical) Once daily for 5-10 years

Source: peptide-db.com ↗
Side effects

Common Side Effects

Morning drowsiness or grogginess (dose-dependent, more common above 50 mg) Dry mouth Dizziness or lightheadedness, particularly upon standing (orthostatic hypotension) Headache Nausea (reduced by taking with food) Blurred vision

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides